Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: A pooled analysis of clinical trials data from Mali

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Sagara, Issaka ^a,b   Piarroux, Renaud ^c   Djimde, Abdoulaye ^a   Giorgi, Roch ^b   Kayentao, Kassoum ^a   Doumbo, Ogobara K ^a   Gaudart, Jean ^b  

^a Sociétés   (Mali)

^b AIX MARSEILLE UNIV   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Artemisinin; Clinical trials; Delayed anaemia; Malaria; Plasmodium falciparum; Uncomplicated

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS PYRIMETHAMINE PLUS SULFADOXINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRIMETHAMINE PLUS SULPHADOXINE; ARTESUNATE PLUS PYRIMETHAMINE PLUS SULPHAMETHOXYPYRAZINE; ARTESUNATE PLUS PYRONARIDINE; CHLOROQUINE; HEMOGLOBIN; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFALENE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISIN; LACTONE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALI; MONOTHERAPY; RISK FACTOR; COMPLICATION; DRUG COMBINATION; FEMALE; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANEMIA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; LACTONES; MALARIA, FALCIPARUM; MALE; MALI; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84907580923     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-358     Document Type: Article

References (27)

1. WHO, World Malaria Report Geneva: World Health Organization 2013
2. WHO, Fact sheets N°94 2014 http://www.who.int/mediacentre/factsheets/fs094/en/
3. WHO, Guidelines for the Treatment of Malaria Geneva: World Health Organization 2 2010 http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf
4. WHO, Guidelines for the Treatment of Malaria Geneva: World Health Organization 2 2011
5. WHO/GMP, Information Note on Delayed Haemolytic Anaemia following Treatment with Artesunate World Health Organization 2013 http://www.who.int/malaria/publications/atoz/who-note-delayed-haemolytic-anaemia-oct13.pdf
6. Post treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP, Malar J 2012 11 169 10.1186/1475-2875-11-169 22594446
7. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Malar J 2012 11 102 10.1186/1475-2875-11-102 22462806
8. Severe falciparum malaria with prolonged haemolytic anemia after successful treatment with intravenous artesunate. Itoda I, Yasunami T, Kikuki K, Yamaura H, Totsuka K, Yoshinaga K, Teramura M, Mizoguchi H, Hatabu T, Kano S, Kansenshogaku Zasshi 2002 76 600 603 12325318
9. Intravenous artesunate for severe malaria in travelers, Europe. Zoller T, Junghanss T, Kapaun A, Gjørup I, Richter J, Hugo- Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H, Emerg Infect Dis 2011 17 771 777 10.3201/eid1705.101229 21529383
10. Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. De Nardo P, Oliva A, Giancola ML, Ghirga P, Mencarini P, Bibas M, Nicastri E, Antinori A, Corpolongo A, Infection 2013 41 863 865 10.1007/s15010-013-0451-x 23553281
11. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Corpolongo A, De Nardo P, Ghirga P, Gentilotti E, Bellagamba R, Tommasi C, Paglia MG, Nicastri E, Narciso P, Malar J 2012 11 91 10.1186/1475-2875-11-91 22453057
12. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Zwang J, Ndiaye JL, Djimdé A, Dorsey G, Mårtensson A, Karema C, Olliaro P, Malar J 2012 11 25 10.1186/1475-2875-11-25 22276858
13. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, Toure S, Sanogo K, Dama S, Sidibe B, Kone A, Thera MA, Plowe CV, Doumbo OK, Djimde AA, Am J Trop Med Hyg 2012 87 23 28 10.4269/ajtmh.2012.12-0058 22764287
14. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Kayentao K, Doumbo OK, Pénali LK, Offianan AT, Bhatt KM, Kimani J, Tshefu AK, Kokolomami JH, Ramharter M, de Salazar PM, Tiono AB, Ouédraogo A, Bustos MD, Quicho F, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Malar J 2012 11 364 10.1186/1475-2875-11-364 23113947
15. Pyronaridine-artesunate Study Team: Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Lancet 2010 375 1457 1467 10.1016/S0140-6736(10)60322-4 20417857
16. Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O, Malar J 2009 8 125 10.1186/1475-2875-8-125 19505304
17. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Sagara I, Fofana B, Gaudart J, Sidibe B, Togo A, Toure S, Sanogo K, Dembele D, Dicko A, Giorgi R, Doumbo OK, Djimde AA, Am J Trop Med Hyg 2012 87 50 56 10.4269/ajtmh.2012.11-0649 22764291
18. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, Traore H, Kone Y, Guirou EA, Saye R, Traore B, Djimde A, Doumbo OK, Malar J 2009 8 5 10.1186/1475-2875-8-5 19128455
19. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK, Am J Trop Med Hyg 2008 79 655 661 18981499
20. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, Thera MA, Sogoba M, Fofana M, Ouattara A, Sissoko M, Jansen HF, Doumbo OK, Am J Trop Med Hyg 2006 75 630 636 17038684
21. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK, Am J Trop Med Hyg 2008 78 455 461 18337343
22. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging amodiaquine and SP resistance in Mali. Tekete M, Djimde AA, Beavogui AH, Maiga H, Sagara I, Fofana B, Ouologuem D, Dama S, Kone A, Dembele D, Wele M, Dicko A, Doumbo OK, Malar J 2009 26 34
23. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, Ndiaye I, Barry A, Cissé B, Lameyre V, Gaye O, Malar J 2011 10 237 10.1186/1475-2875-10-237 21838909
24. Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Olliaro P, Djimdé A, Dorsey G, Karema C, Mårtensson A, Ndiaye JL, Sirima SB, Vaillant M, Zwang J, Am J Trop Med Hyg 2011 85 619 625 10.4269/ajtmh.2011.11-0154 21976561
25. Simultaneous determination of phagocytosis of Plasmodium falciparum-parasitized and non-parasitized red blood cells by flow cytometry. Gallo V, Skorokhod OA, Schwarzer E, Arese P, Malar J 2012 11 428 10.1186/1475-2875-11-428 23259636
26. Immune hemolytic anemia associated with drug therapy. Garratty G, Blood Rev 2010 24 143 145 10.1016/j.blre.2010.06.004 20650555
27. Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats. Clark RL, Brannen KC, Sanders JE, Hoberman AM, Birth Defects Res B Dev Reprod Toxicol 2011 92 52 68 10.1002/bdrb.20282 21312322